We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Celgene, Novartis File Suit to Block Generic Ritalin
Celgene, Novartis File Suit to Block Generic Ritalin
March 6, 2007
Ritalin manufacturer Celgene, and its distributor, Novartis, could experience major losses in revenue if they lose patent litigation in federal court to block a generic version of their attention-deficit/hyperactivity disorder (ADHD) treatment, according to Celgene.